Clinical Trial Update: A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

View source ↗

Summary

Biogen-sponsored study leveraging EU MS registry data to assess the incidence of anti-natalizumab antibodies in relapsing-remitting multiple sclerosis patients …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Natalizumab (natalizumab)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis | Status: ACTIVE_NOT_RECRUITING